Document is current
Any future updates will be listed below
-
Authors
Malle, Louise
Patel, Roosheel S.
Martin-Fernandez, Marta https://orcid.org/0000-0003-4671-6349
Stewart, O Jay https://orcid.org/0000-0001-6071-760X
Philippot, Quentin
Buta, Sofija
Richardson, Ashley https://orcid.org/0000-0002-1700-9162
Barcessat, Vanessa https://orcid.org/0000-0002-0256-2862
Taft, Justin
Bastard, Paul
Samuels, Julie https://orcid.org/0000-0001-5184-0390
Mircher, Clotilde
Rebillat, Anne-Sophie
Maillebouis, Louise
Vilaire-Meunier, Marie
Tuballes, Kevin https://orcid.org/0000-0002-5899-7080
Rosenberg, Brad R. https://orcid.org/0000-0002-5885-1276
Trachtman, Rebecca
Casanova, Jean-Laurent
Notarangelo, Luigi D. https://orcid.org/0000-0002-8335-0262
Gnjatic, Sacha https://orcid.org/0000-0001-5643-9520
Bush, Douglas
Bogunovic, Dusan https://orcid.org/0000-0002-9277-3232
- License Information
-
More Information
Article History
Received: 16 December 2021
Accepted: 17 January 2023
First Online: 22 February 2023
Competing interests
: D.B. is the founder and part owner of Lab11 Therapeutics. S.G. reports other research funding from Genentech, Boehringer-Ingelheim, Celgene, Takeda, and Regeneron.
Free to read: This content has been made available to all.
